Free Trial
Want deep insights into your competitors & competitive landscape? Try Patsnap Eureka!

Top 20 Key Players companies in Nicotinamide mononucleotide
by Most Patent Filings in the China in 2022

The Nicotinamide mononucleotide top 20 is Discovery PatSnap’ annual ranking of the top 20 Most Patent Filings Nicotinamide mononucleotide Key Players in the China. Discovery has identified the top key players, startups & unicorns, fast-growings, news entrants in 2022, ranking from differnt perspectives, including patent filing intensity, academic research capability, news media heat. The company list is generated from various data types.
Nicotinamide mononucleotide ("NMN", "NAMN", and "β-NMN") is a nucleotide derived from ribose and nicotinamide. Like nicotinamide riboside, NMN is a derivative of niacin, and humans have enzymes that can use NMN to generate nicotinamide adenine dinucleotide (NADH).
#
Company Name
Region
Tech Topics
Total
1
Patent: 5
2
Nutrition,Health care,Arachidonic acid,
...[+2]
Patent: 3
3
Medicine,Bead,Cardiovascular agent,
...[+2]
Patent: 3
4
Patent: 3
5
Health care,Genetic engineering,Enzyme,
...[+2]
Patent: 2
6
Patent: 2
7
Patent: 2
8
Zhongke Health Industry Group Corp., Ltd
Patent: 2
9
Patent: 1
10
Patent: 1
11
Health care,Research system,International health,
...[+2]
Patent: 1
12
Patent: 1
13
Patent: 1
14
Patent: 1
15
Patent: 1
16
Patent: 1
17
Plasma Volume Expander,Antibiotics,Drug,
...[+1]
Patent: 1
18
Patent: 1
19
Patent: 1
20
Patent: 1
Page generation time: Jun 16 2025